ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2022
Construction of Predictive Model for Type 2 Diabetic Retinopathy Based on Extreme Learning Machine.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Predicting acute and chronic diabetes complications among adults newly diagnosed with diabetes: development and validation of dynamic risk prediction models.Nature communications · 2026Article
- Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics.Briefings in bioinformatics · 2026Article
- An enhanced machine learning algorithm for type 2 diabetes prognosis with a detailed examination of Key correlates.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The common cause of blindness in people with type 2 diabetes (T2D) is diabetic retinopathy (DR). Early fundus examinations have been shown to prevent vision loss, but routine ophthalmic screenings for patients with diabetes present significant financial and material challenges to existing health-care systems. The purpose of this study is to build a DR prediction model based on the extreme learning machine (ELM) and to compare the performance with the DR prediction models based on support machine vector (SVM), K proximity (KNN), random forest (RF) and artificial neural network (ANN). Methods: From January 1, 2020 to November 31, 2021, data were collected from electronic inpatient medical records at Lu'an Hospital of Anhui Medical University in China. An extreme learning machine (ELM) algorithm was used to develop a prediction model based on demographic data and blood testing and urine test results. Several metrics were used to evaluate the model's performance: (1) classification accuracy (ACC), (2) sensitivity, (3) specificity, (4) Precision,(5) Negative predictive value (NPV), (6) Training time and (7) area under the receiver operating characteristic (ROC) curve (AUC). Results: In terms of ACC, Sensitivity, Specificity, Precision, NPV and AUC, DR prediction model based on SVM and ELM is better than DR prediction model based on ANN, KNN and RF. The prediction model for diabetic retinopathy based on elm is the best among them in terms of ACC, Precision, Specificity, Training time and AUC, with 84.45%, 83.93%, 93.16%,1.24s, and 88.34%, respectively. The DR prediction model based on SVM is the best in terms of sensitivity and NPV, which are, respectively, 70.82% and 85.60%. Conclusion: According to the findings of this study, the model based on the extreme learning machine presents an outstanding performance in predicting diabetic retinopathy thus providing technological assistance for screening of diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.